Forbes Medi-Tech Inc.
OTC Bulletin Board : FMTI

August 23, 2005 08:00 ET

Forbes Medi-Tech Makes Valuable Addition to the Board of Directors

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 23, 2005) - Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) -

Forbes Appoints Guy Miller from Edison Pharmaceuticals as Director

Forbes Medi-Tech Inc. announced today the appointment of Guy Miller, CEO of Edison Pharmaceuticals, to the Forbes Medi-Tech Board of Directors.

"Dr. Miller brings a successful history of R&D and operational experience in the life science industry which compliments our development and commercialization initiatives," said Charles Butt, President & CEO of Forbes Medi-Tech Inc. "He will be a welcome addition to the Board as we prepare for the upcoming US Phase II trial of FM-VP4."

Guy Miller, MD, PhD, is Chief Executive Officer of Edison Pharmaceuticals. Prior to Edison, he founded Galileo Pharmaceuticals, and was its Chairman and CEO from 1995-2005. Dr. Miller was an Assistant Professor at Johns Hopkins University School of Medicine and currently holds appointments as Adjunct Professor, University of North Carolina, School of Public Health and as Clinical Instructor, Stanford University School of Medicine, where he is an attending physician in Critical Care Medicine.

About Forbes Medi-Tech Inc.

Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.

This News Release contains forward-looking statements regarding the Company, its operations and future prospects, which statements can be identified by the use of forward-looking terminology such as "will", "prepare for", "upcoming", "strategy", "develop", or comparable terminology referring to future events or results or terminology referring to future dates. The Company's expectations could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including uncertainty whether the U.S. Phase II trial of FM-VP4 will occur as planned or at all or will be successful; uncertainty whether FM-VP4 will be commercialized; uncertainty whether the Company will realize is strategies and vision; the need for additional clinical trials, the occurrence and success of which is not assured; intellectual property risks; the need for regulatory approvals, which are not assured and which may be denied or withdrawn; manufacturing risks and the need to manufacture to regulatory standards; product liability and insurance risks; the risk of unknown side effects; intellectual property risks; the effect of competition; and the Company's need for future funding; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's reports filed with the Canadian and U.S. securities regulatory authorities from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.

NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release.

Contact Information